Navigation Links
400,000 Patients Is The Latest Estimate Of Those Needlessly Dying Due To Medical Errors, And Twice As Many As Any Previous Estimate
Date:10/24/2013

Greenville, SC (PRWEB) October 24, 2013

Institute of Medicine To Err Is Human (http://is.gd/2MSBhR) raised national awareness of the tragic rate of needless hospital deaths annually in 2000. The basis of 98,000 annual needless hospital deaths used in To Err Is Human had resulted from four years of research in New York state hospitals ending in 1990.

Ten years after To Err Is Human Sully Sullenberger, Hero on the Hudson, (http://is.gd/26uxXj) estimated that there were 200,000 preventable deaths each year in our hospitals, and that is like having 20 Boeing 747 airliners going down each week.

Now John T. James, PhD in Journal of Patient Safety, September 2013 (http://is.gd/GzKOg3) offers a much higher estimate of annual deaths due to medical errors. Using Global Trigger Tools James estimates, “…the true number of premature deaths associated with preventable harm to patients was estimated at more than 400,000 per year. Serious harm seems to be 10 to 20 fold more common than lethal harm.”

In Find The Black Box (http://is.gd/UK4Uk0) Williams identifies the two fundamentals of all medical care that have always been ignored, or more probably unrecognized in all of the efforts to improve the quality of healthcare and patient safety; all medical care is local and states license doctors.

Those two fundamental facts of all patient care were never recognized in To Err Is Human, and have never been recognized in the voluminous quality of healthcare literature since. As a result, the current rate of needless hospital deaths has at least doubled that original 1990 estimate, and according to James,
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. BioNeutral Group Receives $400,000 in Equity Financing
2. Mold and Leaks on Roofs Expected to Cost Fillmore Middle School $400,000, My Cleaning Products Recommends a Product That Could Cut Mold Treatment Expenses by $1,000
3. Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients
4. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
5. New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
6. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
7. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
8. Candelis and Microsoft Team Up to Empower Patients
9. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... PARIS , July 30, 2015 ... leader, reports results for the second quarter of ... the group,s results and its performance in different ... transcript:  http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire ... - Q2 results - Performance drivers ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... manufacturer and supplier, announces the launch of their 2nd generation cell therapy POD® ... current miniPOD CT, but it also represents a new POD® design. , ...
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2
... Corporation (OTC Bulletin Board: MFLU) announced today that the ... Monday, November 2, 2009, after the closing of the ... ) , Michael C. Ferrara, President and Chief ... Finance and Chief Accounting Officer, will host a conference ...
... -- In response to requests from clients, Schulman ... , The Schulman Canadian Board,s first official meeting is ... are conducted in both the U.S. and Canada, Canadian and ... to maintain consistency. , "Our clients have asked us to ...
... The Board of Directors of Biomoda, Inc. (OTC Bulletin ... cancer detection medical diagnostics company, has elected Maria Zannes ... the Biomoda Board May 1, 2008. , "Maria,s extraordinary ... perfect individual to safeguard our commitment to good corporate ...
Cached Biology Technology:Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 2Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 3Schulman Associates IRB Establishes an Institutional Review Board in Canada 2Biomoda Board of Directors Names New Corporate Secretary 2
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... scleroderma has slowed Tracy Zinn but it has not stopped ... accommodating employer, Zinn is now in her 13th year as ... But, many with the incapacitating disease are not as fortunate. ... people with systemic scleroderma, also known as systemic sclerosis, is ...
... 2011 DigitalPersona, Inc. , a global provider ... Pizza Hut™ franchisee Rage, Inc. has rolled out ... locations throughout the east coast in South Carolina, North ... By deploying fingerprint biometrics as a part of their ...
... 2001--Eating nuts every day could help control Type 2 ... from St. Michael,s Hospital and the University of Toronto. ... Diabetes Care , a team of researchers led ... Nutritional Sciences; St. Michael,s Hospital Risk Factor Modification Centre) ...
Cached Biology News:Scleroderma study identifies roadblocks to employment 2Scleroderma study identifies roadblocks to employment 3Pizza Hut Franchisee Saves Dough by Slicing Payroll Fraud and Leavening Store Revenue with Digital Persona Fingerprint Biometrics 2A 'nutty' solution to type 2 diabetes management 2
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Hepatocyte Differentiation Environment...
Biology Products: